BioStock: Abliva’s KL1333 development plan receives OK from FDA
As Abliva prepares for its next steps in the clinical development of KL1333, the company has received good news from FDA. At a pre-Investigational New Drug meeting, FDA presented positive feedback to Abliva’s plans for continuation with the project aimed at developing a new treatment of primary mitochondrial diseases.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se